Topics
Longevity and public-health stories with a phone-readable number — years lived, vaccines, and lives counted.
Browse all stories
·Health
Nature Medicine on 16 September 2026 published 38 sex-specific biological aging clocks across 15 organs from Columbia’s MULTI Consortium; brain MRI clocks predicted MCI→AD with HR 1.74 in men and 2.25 in women per 1-SD older brain — research tools, not a consumer longevity score.
Read the story
·Science & Technology
On 17 September 2026 Science published Stanford’s Virtual Biotech: more than 37,000 AI agents curated 55,984 trials and found cell-type-specific targets were 40% more likely to clear Phase I–II, 48% more likely to reach market, and linked to 32% fewer adverse events — then proposed a B7-H3 antibody–drug conjugate for lung cancer. Computational strategy, not a Stanford FDA approval.
Read the story
·Health
On 16 September 2026 Nature Medicine published PANXEON, a City of Hope–led blood assay combining a 10-microRNA exosome signature with CA19-9. In a prospective study of 1,852 people across four countries, the miRNA signature alone hit AUC 88.6% and 83.8% sensitivity for early-stage pancreatic ductal adenocarcinoma; with CA19-9, sensitivity reached 86.8% for stage I–II. It is a biomarker study, not an FDA-cleared screening test.
Read the story
·Science & Technology
On 12 September 2026, Wake Forest’s GeroScience pooled analysis of seven randomized calorie-restriction trials (n=829; mean age 67.5) found CR improved a six-marker aging blood index by −2.2 points versus no-CR; only 48.5% of that effect was mediated by weight loss. A biomarker index win, not proven extra years of life.
Read the story
·Science & Technology
A Salk-led Nature Aging atlas built from more than 600 frontal-cortex brains reports 1,067 microproteins missing from reviewed UniProt catalogs — including a 63-amino-acid MKKS product downregulated in Alzheimer’s that hits microglial mitochondria. It is a map, not a drug.
Read the story
·Science & Technology
On 8 September 2026, Google DeepMind released AlphaGenome Atlas and ranked all 9 billion possible single-letter DNA mutations in the human genome. The free AVI score prioritizes coding and non-coding variants for research. Early UK Biobank work found 22% more rare non-coding associations. Atlas is a predictive catalogue, not a clinical diagnosis.
Read the story
·Health
On 4 September 2026 the FDA granted accelerated approval to camizestrant (Etcamah, AstraZeneca) with a CDK4/6 inhibitor for adults with HR+/HER2− advanced breast cancer when an ESR1 mutation appears on an FDA-authorized test during AI + CDK4/6 therapy. In SERENA-6 (n=315), median PFS was 16 months vs 9.2 months (HR 0.44). OS is immature; confirmatory trials are required.
Read the story
·Science & Technology
In Baby's First Years, a U.S. randomized trial published in Nature Human Behaviour on 8 September 2026, mothers with low income who received $333 a month for their child's first four years had 4-year-olds with slower DunedinPACE biological-aging scores (−0.17 SD) than families getting $20 a month.
Read the story
·Science & Technology
On 7 September 2026, Insilico Medicine and collaborators published in Nature Biotechnology a Phase IIa exploratory analysis showing that rentosertib, an AI-designed TNIK inhibitor for idiopathic pulmonary fibrosis, lowered predicted biological age on all six proteomic aging clocks tested in 42 patients. Peak signal was about 3–4 years younger at week 4 on 30 mg twice daily — exploratory biomarkers in sick lungs, not an approved anti-aging pill.
Read the story
·Science & Technology
On 20 August 2026 the FDA cleared C2N Diagnostics’ PrecivityAD2 blood test to help evaluate Alzheimer’s disease in adults aged 40 and older with cognitive symptoms. In a study of 1,142 people, a Positive result had 97.6% PPV and a Negative result 93.1% NPV against amyloid PET or CSF. The test is not a stand-alone diagnosis or a population screen.
Read the story
·Science & Technology
On 2 September 2026, a UC Berkeley–led team with Copenhagen and NIA co-authors reported in Nature that late-life semaglutide raised median lifespan in female C57BL/6 mice from 742 to 834 days — about 12%. Treated mice lived roughly 100 days longer on average and outpaced matched calorie restriction on memory and glucose control. This is a mouse study, not a human longevity trial, and it does not prove Ozempic or Wegovy extends human lifespan.
Read the story
·Health
On 26 August 2026 University of Oxford researchers reported in Nature Medicine that adults 60 and older who received the recombinant shingles vaccine (mostly Shingrix) had a 9% lower cardiovascular-disease burden over seven years than matched people who had just received the older live vaccine (mostly Zostavax). The print is 36,460 people in each arm. This is a natural experiment, not a randomized trial, and it is not a comparison with being unvaccinated.
Read the story
·Health
On 27 August 2026 Charité – Universitätsmedizin Berlin reported in Nature Medicine the first prospective trial of a CD19 CAR T-cell therapy in rheumatoid arthritis. Six people with treatment-refractory, ACPA-positive disease received a single infusion of mivocabtagene autoleucel. Disease activity improved in all six. Three hit DAS28-CRP remission and an ACR70 response, and three were off all RA drugs at last follow-up. This is a six-person Phase 1, not a cure and not an approved RA treatment.
Read the story
·Health
On 26 August 2026 the FDA approved RASONQUE (daraxonrasib), a once-daily pill for adults with metastatic pancreatic adenocarcinoma who already had systemic therapy or who cannot take multi-agent chemo. Tablets are in U.S. pharmacies now at a $39,800 wholesale acquisition cost for 30 days. The Phase 3 numbers — median overall survival 13.2 months versus 6.7 — were already in NEJM and at ASCO. This is not a cure, and it is not first-line for everyone.
Read the story
·Health
WHO and Africa CDC on 27 August 2026 welcomed the end of Uganda’s Bundibugyo Ebola outbreak after 42 days with no new confirmed case. Uganda recorded 20 cases, 18 recoveries and two deaths. The DRC outbreak continues, and there is still no approved vaccine for this species.
Read the story
·Health
Merck and Moderna said on 19 August 2026 that adjuvant intismeran autogene plus Keytruda met recurrence-free and distant metastasis-free survival versus Keytruda alone in 1,137 patients with resected stage IIB–IV melanoma — the first positive Phase 3 for an individualized mRNA cancer therapy. Phase 3 hazard ratios are not public yet; overall survival is still maturing.
Read the story
·Health
On 24 August 2026 Tedros told WHO’s African Regional Committee that malaria vaccines are in 25 countries and Burkina Faso cases have already fallen by nearly a third. National data Gavi published from a February 2026 briefing put 2025 cases at 7,329,278, down 32% from 10,805,020, and deaths at 1,979, down 44% from 3,523. That is not elimination, and it is not a vaccine-only result.
Read the story
·Health
NCHS Vital Statistics Rapid Release no. 44 (2 July 2026) puts the provisional 2025 U.S. age-adjusted death rate at 689.2 per 100,000 — 4.6% below the final 2024 rate of 722.1, covering 3,094,593 deaths and 99.9% of certificates as of 10 May 2026. NCHS calls it the lowest death rate recorded. The file does not compute life expectancy; that 2024 print (79.0 years) is Data Brief 548.
Read the story
·Health
Vorontsov et al. in Nature Medicine (31 July 2026) trained PRISM2 on 2,350,518 whole-slide images from 685,507 specimens and 200,692 patients, plus 14 million question–answer pairs. Prompt-based inference matches or exceeds (P < 0.05) Paige Prostate, Paige Breast and Paige BLN on their own test sets. Pan-cancer linear-probe AUC 0.967. Not a prospective reader trial.
Read the story
·Health
WHO AFRO closed poliovirus type 2 outbreaks in Burundi, Ghana, Guinea-Bissau, the Republic of Congo and Uganda after OBRA teams reviewed surveillance, lab and epi data from January to June 2026. Closure is technical, not eradication — Madagascar is the caution WHO cites.
Read the story
·Health
The WHO verified that Chile has eliminated leprosy as a public health problem, becoming the first country in the Americas to achieve this milestone.
Read the story
·Science & Technology
Phase 3 data published in Nature Medicine indicate sustained protection from Butantan's vaccine against symptomatic dengue and, most importantly, against severe cases. The potential impact on hospitalizations in Brazil is high.
Read the story
·Health
CDC’s NCHS final 2024 mortality data put U.S. life expectancy at 79.0 years, up 0.6 from 78.4 in 2023, the highest NCHS has recorded. A second report the same day recorded a 26.2% drop in the drug-overdose death rate.
Read the story
·Health
WHO’s World Health Statistics 2025 report shows long-term gains in healthy life expectancy before COVID-19, but a pandemic-era reversal, slowing progress toward SDG targets, and persistent financial and workforce constraints across health systems.
Read the story